HENDERSON, NV / ACCESSWIRE / February 12, 2019 / Below are several companies in the biotech space that are making news and drawing investor interest. These companies have the potential to make investors serious profits.
An oversold biotech with potential we really like is Delcath Systems, Inc. (DCTH). Last September, the stock reached highs above $8, and is now sitting around support at $0.26. With promising liver cancer treatments in late-stage development (clinical trials), a new licensing deal with a projected value of up to $45 million, there is an opportunity to consider here. With low awareness among investors, the Company may not have reached a proper market valuation, and that's why we think you should consider researching DCTH today.
An interventional oncology company focused on treating liver cancers with possible upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $3.667M, Share Price: $0.3285), is an interventional oncology company focused on treating liver cancers. The Company has had some noteworthy developments in the last year. They announced an amendment to their Phase 3 clinical trial in ocular melanoma liver metastases, raised $7 million via a right offering, and had data published in European Radiology among several other milestones. The Company could be positioned to benefit from a rally in biotech stocks.
Most recently, DCTH just announced they've received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. This is a significant market opportunity for DCTH, since according to the World Health Organization, liver and bile duct cancers account for over 10,000 deaths in Brazil annually. To develop the Brazilian market, the Company intends to align with a local strategic partner.
DCTH made news recently after it entered a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
DCTH also announced the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.
With more news on the horizon, there may be the potential for an event-driven rally. Do your due diligence on DCTH now.
Proteostasis Therapeutics, Inc. (PTI) (Market Cap: $192.209M, Share Price: $3.91) clinical-stage biopharmaceutical company dedicated to treating cystic fibrosis, announced that Emmanuel Dulac, PharmD, Ph.D., and Kim Cobleigh Drapkin, CPA, have been appointed to the Company's Board of Directors. Both the new appointees will hopefully bring their years of leadership experience to the Proteostasis team.
Trevena, Inc. (TRVN) (Market Cap: $138.485M, Share Price: $1.50) is a biopharmaceutical company working on opioid alternatives for the management of moderate-to-severe acute pain.
Cronos Group, Inc. (CRON) (Market Cap: $3.489B, Share Price: $16.44) announced in early December 2018 that it had entered into a subscription agreement with Altria Group, Inc., one of the leading tobacco brands in the world, pursuant to which Altria agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company.
Cara Therapeutics, Inc. (CARA) (Market Cap: $645.744M, Share Price: $16.37) announced completion of enrollment in the KALM-1 Phase 3 trial of KORSUVA™ (CR845/ difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). More than 350 hemodialysis patients with CKD-aP have now been randomized across approximately 60 clinical sites in the United States.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC
View source version on accesswire.com: